The May 2017 release of a new MDR in the Official Journal of the European Union marked the start of a three-year transitional period within the medical devices industry. Manufacturers, suppliers, notified bodies, and national competent authorities must comply with the new regulation which was to take effect in May 2020 but has been postponed one year due to the COVID-19 virus. The changes made in the new MDR are significant and immense. This paper will take you through the key points to understand.
Basics of Regulatory Strategy
Driving development of drug products from pre-IND through marketing.
Data Sharing & Anonymization - Current Overview of Data Sharing within Clinical Trial Transparency
Clinical trial transparency has emerged in recent years as a key function within pharmaceutical and academic organizations. Although trial…
New Ways to Think Strategically About Clinical Trial Transparency
Clinical teams face increasing pressure to adapt to recent advances within trial transparency. Clinical trial transparency now incorporates sharing…